High numbers of active caspase 3-positive Reed-Stemberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome

Blood

Volumn 100, Issue 1, 2002, Pages 36-42

  Dukers, Danny F ^a   Meijer, Chris J L M ^a   Ten Berge, Rosita L ^a   Vos, Wim ^a   Ossenkoppele, Gert J ^a   Oudejans, Joost J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; PROTEIN P21; PROTEIN P53;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CELL KILLING; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; STRESS; TREATMENT OUTCOME; TUMOR CELL;

EID: 0036659922     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.36     Document Type: Article

References (63)

1. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1083.
2. Kanzler H, Küppers R, Hansmann ML. Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;84:1495-1505.
3. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443-1450.
4. Müschen M, Rajewsky K, Bräuninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000;191:387-394.
5. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte-predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97:496-501.
6. Theil J, Laumen H, Marafioti T, et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood. 2001;97:3191-3196.
7. Hollowood K, Goodlad JR. Germinal centre cell kinetics. J Pathol. 1998;185:229-233.
8. Liu YJ, Arpin C, de Bouteiller O, et al. Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Semin Immunol. 1996;8:169-177.
9. Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol. 1998;16:471-493.
10. Josting A, Wolf J, Diehl V. Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol. 2000;12:403-411.
11. Brice P. Prognostic factors in advanced Hodgkin's disease: can they guide therapeutic decisions? N Engl J Med. 1998;339:1506-1514.
12. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-I/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574-577.
13. Los M, Herr I, Friesen C, Fulda S, SchulzeOsthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood. 1997;90:3118-3129.
14. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive-and drug-resistant tumor cells. Cell Death Differ. 1999;6:471-480.
15. Belka C, Schmid B, Marini P, et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene. 2001;20:2190-2196.
16. Belka C, Marini P, Lepple-Wienhues A, et al. The tyrosine kinase Ick is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation. Oncogene. 1999;18:4983-4992.
17. Pervaiz S, Seyed MA, Hirpara JL, Clement MV, Loh KW. Purified photoproducts of merocyanine 540 trigger cytochrome C release and caspase 8-dependent apoptosis in human leukemia and melanoma cells. Blood. 1999;93:4096-4108.
18. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92:3804-3816.
19. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 1999;93:3053-3063.
20. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol. 1999;17:781-828.
21. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95:4997-5002.
22. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and 1-10 in a caspase-9-dependent manner. J Cell Biol. 1999;144:281-292.
23. Li PF, Dietz R, von Harsdorf R. P53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J. 1999;18:6027-6036.
24. Stennicke HR, Jurgensmeier JM, Shin H, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem. 1998;273:27084-27090.
25. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature. 1995;377:446-448.
26. Darmon AJ, Ley TJ, Nicholson DW, Bleackley RC. Cleavage of CPP32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation. J Biol Chem. 1996;271:21709-21712.
27. Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A, Casciola-Rosen L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity. 1998;8:451-460.
28. Heibein JA, Goping IS, Barry M, et al. Granzyme B-mediated cytochrome c release is regulated by the bcl-2 family members bid and Bax. J Exp Med. 2000;192:1391-1402.
29. Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med. 2000;192:1403-1414.
30. Alimonti JB, Shi L, Baijal PK, Greenberg AH. Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition. J Biol Chem. 2001;276:6974-6982.
31. Dukers DF, Oudejans JJ, Vos W, ten Berge RL, Meijer CJLM. Apoptosis in B cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method. J Pathol. 2002;196:307-315.
32. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53:3976-3985.
33. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol. 1997;75:337-349.
34. Casciola-Rosen L, Nicholson DW, Chong T, et al. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med. 1996;183:1957-1964.
35. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 1994;371:346-347.
36. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA. Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death: involvement of serine but not cysteine proteases. Am J Pathol. 1997;151:1205-1213.
37. Jaffe ES, Harris NL, Stein H, Vardiman JW. Hodgkin lymphoma in the World Health Organisation classification of tumours: pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyons, France: IARC Press; 2001:237-254.
38. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification, I: application to immunoassays. J Immunol Methods. 1989;125:279-285.
39. Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class 1 expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin disease. Blood. 1996;87:3844-3851.
40. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood. 1997;89:1376-1382.
41. Chhanabhai M, Krajewski S, Kralewska M, Wang HG, Reed JC, Gascoyne RD. Immunohistochemical analysis of interleukin-1beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease. Blood. 1997; 90:245-2455.
42. Rosenberg SA. The treatment of Hodgkin's disease. Ann Oncol. 1994;5:17-21.
43. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993;11:2258-2272.
44. Chilosi M, Doglioni C, Magalini A, et al. p21/WAF1 cyclin-kinase inhibitor expression in nonHodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood. 1996;88:4012-4020.
45. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 2000;6:1029-1035.
46. Houghton JA. Apoptosis and drug response. Curr Opin Oncol. 1999;11:475-481.
47. Sanchez-Beato M, Piris MA, Martinez-Montero JC, et al. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. J Pathol. 1996;180:58-64.
48. Montesinos-Rongen M, Roers A, Küppers R, Rajewsky K, Hansmann ML. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood. 1999;94:1755-1760.
49. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
50. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
51. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921-1925.
52. Shinozawa I, Inokuchi K, Wakabayashi I, Dan K. Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies. Leuk Res. 2000;24:965-970.
53. Xerri L, Parc P, Brousset P, et al. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol. 1996;92:900-906.
54. Xerri L, Hassoun J, Devilard E, Birnbaum D, Birg F. BCL-X and the apoptotic machinery of lymphoma cells. Leuk Lymphoma. 1998;28:451-458.
55. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
56. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
57. Izban KF, Ergin M, Huang Q, et al. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol. 2001;14:297-310.
58. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18:3063-3070.
59. Emmerich F, Meiser M, Hummel M, et al. Overexpression of 1 kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood. 1999;94:3129-3134.
60. Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000;191:395-402.
61. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001;409:207-211.
62. Izban KF, Wrone-Smith T, Hsi ED, Schnitzer B, Quevedo ME, Alkan S. Characterization of the Interleukin-1β-converting enzyme/Ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease. Am J Pathol. 1999;154:1439-1447.
63. Wrone-Smith T, Izban KF, Ergin M, Cosar EF, Hsi ED, Alkan S. Transfection of caspase-3 in the caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis. Exp Hematol. 2001;29:572-581.